Provided by Tiger Trade Technology Pte. Ltd.

Enliven Treateutics

26.00
+2.7511.83%
Post-market: 26.120.1200+0.46%19:58 EST
Volume:5.79M
Turnover:155.45M
Market Cap:1.54B
PE:-14.33
High:29.98
Open:23.58
Low:23.27
Close:23.25
52wk High:29.98
52wk Low:13.30
Shares:59.35M
Float Shares:35.00M
Volume Ratio:2.47
T/O Rate:16.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8147
EPS(LYR):-1.8912
ROE:-25.43%
ROA:-17.62%
PB:3.24
PE(LYR):-13.75

Loading ...

Company Profile

Company Name:
Enliven Treateutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
65
Office Location:
6200 Lookout Road,Boulder,Colorado,United States
Zip Code:
80301
Fax:
- -
Introduction:
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Directors

Name
Position
Richard Fair
President, Chief Executive Officer and Director
Richard Heyman
Chairman
Jake Bauer
Director
Lori Kunkel
Director
Mika Derynck
Director
Rahul D. Ballal
Director
Rishi Gupta
Director
Scott Garland
Director

Shareholders

Name
Position
Richard Fair
President, Chief Executive Officer and Director
Anish Patel
Chief Operating Officer
Benjamin Hohl
Chief Financial Officer and Head of Corporate Development
Helen Collins
Chief Medical Officer
Joseph P. Lyssikatos
Chief Scientific Officer
Sam Kintz
Head of Pipeline